Eikon Therapeutics

EIKN · NASDAQ

$8.18+$0.48 (+6.23%)TodayMarket closed ·
Prev close $7.70

Who owns EIKN

Largest institutional holders, from their latest 13F filings

The 10 largest institutions hold 55.3% of EIKN’s shares.

  • Lux Capital Management, LLC10.5%
  • Fidelity Management & Research Company LLC9.1%
  • The Column Group LP7.2%
  • Foresite Capital Management, LLC6.0%
  • Next 6 largest institutions22.5%
  • All other shareholders44.7%
Top institutional holders of EIKN
HolderShares% of shares
Lux Capital Management, LLC5.70M10.52%
Fidelity Management & Research Company LLC4.93M9.11%
The Column Group LP3.89M7.18%
Foresite Capital Management, LLC3.26M6.03%
Abu Dhabi Investment Authority2.82M5.20%
Innovation Endeavors III, L.P.2.72M5.03%
Catalyst4 Inc1.72M3.18%
Merck & Co Inc1.67M3.08%
Mahler International Ltd1.66M3.07%
T. Rowe Price Investment Management, Inc.1.60M2.95%

Largest mutual fund holders

Top mutual fund holders of EIKN
HolderShares% of shares
BGF World Healthscience Fund1.52M2.81%
Fidelity Contrafund1.27M2.35%
Fidelity Select Biotechnology Portfolio1.15M2.13%
American Funds SMALLCAP World Fund1.14M2.11%
T. Rowe Price Small Cap Value Fund926.05K1.71%

Insider trades

Form 4 filings by officers, directors and large holders

Over the last 6 months, insiders bought $1.03M (1 trade) of EIKN on the open market, with no sales.

Latest EIKN insider transactions
InsiderTypeSharesValue
Column Group IV GP, LPBuy89.20K$1.03M

Short interest

Settled Sep 30, 2026

Shares short
6.29M
Days to cover
8.79
% of shares outstanding
11.63%
Average daily volume
716.05K
Change since last report
+15.4%

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.